Cart
sales@molnova.com
Home -
Products -
Others -
Other Targets -
(1E)-3-methoxy-8,12-epoxygermacra-1,7,10,11-tetraen-6-one
(1E)-3-methoxy-8,12-epoxygermacra-1,7,10,11-tetraen-6-one
CAS No. 1393342-06-7
(1E)-3-methoxy-8,12-epoxygermacra-1,7,10,11-tetraen-6-one( —— )
Catalog No. M31993 CAS No. 1393342-06-7
(1E)-3-methoxy-8,12-epoxygermacra-1,7,10,11-tetraen-6-one is a natural product for research related to life sciences.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 603 | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name(1E)-3-methoxy-8,12-epoxygermacra-1,7,10,11-tetraen-6-one
-
NoteResearch use only, not for human use.
-
Brief Description(1E)-3-methoxy-8,12-epoxygermacra-1,7,10,11-tetraen-6-one is a natural product for research related to life sciences.
-
Description(1E)-3-methoxy-8,12-epoxygermacra-1,7,10,11-tetraen-6-one is a natural product for research related to life sciences.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1393342-06-7
-
Formula Weight260.3
-
Molecular FormulaC16H20O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
NBD-F
NBD-F is a fluorescent derivatization compound for amino acid analysis.
-
Peptide YY(3-36), PY...
Peptide YY (PYY) (3-36), Human is an endogenous appetite suppressing peptide. Peptide YY (PYY) (3-36), Human, a neuropeptide Y (NPY) Y2 receptor agonist, is a powerful inhibitor of intestinal secretion.
-
EcAMP3
EcAMP3 is a hairpin-like peptide. EcAMP3 has antifungal and antibacterial activity. EcAMPs precursor family contains seven identical cysteine motifs: C1XXXC2(11–13)C3XXXC4.
